Prevention of clinical and histological signs of MOG-induced experimental allergic encephalomyelitis by prolonged treatment with recombinant human EGF

Epidermal growth factor (EGF) represents the prototype of the group I EGF family. The pleiotropic effects of the EGF have attracted attention on the possibility that it could be implicated in autoimmune diseases, such as Multiple Sclerosis (MS). We show here that treatment with EGF, as a late prophylactic regime, improved the clinical and histological features of EAE, a preclinical model of MS. In silico analysis further corroborated these findings by demonstrating that EGF receptors are less expressed in CNS from patients with MS as compared to controls.

Source: Journal of Neuroimmunology - May 7, 2019 Category: Allergy & Immunology Authors: Ferdinando Nicoletti, Emanuela Mazzon, Paolo Fagone, Katia Mangano, Santa Mammana, Eugenio Cavalli, Maria Sofia Basile, Placido Bramanti, Giuseppe Scalabrino, Alois Lange, Francois Curtin Source Type: research